Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Phase I Multiple Dose Pharmacokinetic Study of Lycopene Delivered in a Well-Defined Food-Based Lycopene Delivery System (Tomato Paste-Oil Mixture) in Patients at Increased Risk for Developing Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00416325
• Other study ID #: UIC-2000-0931
• Secondary ID: CDR0000467322
• Status: Completed
• Phase: Phase 1
• First received: December 27, 2006
• Last updated: June 25, 2013
• Est. completion date: September 2006

Study information

• Verified date: September 2006
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of lycopene, a substance found in tomatoes, may keep prostate cancer from forming in patients at high risk of developing prostate cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of lycopene in preventing prostate cancer in patients who are at high risk of developing prostate cancer.

Description:

OBJECTIVES:

• Define the toxicity and safety of lycopene administered as a food-based delivery system as a chemoprevention agent in patients who are at a high risk of developing prostate cancer.

• Define the pharmacokinetics and tissue distribution in patients receiving this regimen.

• Characterize surrogate endpoint biomarkers (SEBs) in the peripheral blood, buccal mucosa, and the prostate itself, which will provide evidence of biological activity relevant to a chemoprevention effect.

• Characterize the oxidative stress state of the individual by studies of DNA oxidation in the prostate and buccal mucosa, as well as DNA oxidation and lipid peroxidation within the peripheral blood.

• Define the effects of lycopene through a food delivery system on prostate histology (prostatic intraepithelial neoplasia), markers of cellular proliferation [PCNA], and apoptosis in the prostate.

• Evaluate the effects of lycopene on the serum levels of total prostate-specific antigen (PSA), free PSA, and PSA density.

• Provide the basic knowledge in reference to toxicity, pharmacokinetics, and SEBs needed to proceed to a large phase II or III lycopene study in these patients.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive oral lycopene in tomato paste and olive oil, once, twice, or three times daily for 3 months.

Cohorts of 6 patients receive escalating doses of lycopene until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Patients undergo buccal scrapings and blood collection periodically during study for pharmacokinetics and biomarker studies.

After completion of study treatment, patients are followed for 1 month.

PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: September 2006
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 35 Years to 75 Years

Eligibility

DISEASE CHARACTERISTICS:

• Elevated prostate-specific antigen (PSA), meeting 1 of the following criteria:

• PSA > 4.0 ng/mL for patients at any age

• PSA > 2.0 ng/mL for patients 35 to 49 years of age

• PSA rise (velocity) of > 0.75 ng/mL over the past year

• Has undergone a prostate biopsy* (following findings of elevated PSA) within the past 180 days that failed to reveal prostate cancer

• Prostate intraepithelial neoplasia allowed NOTE: *At least 4 core biopsies are considered acceptable

PATIENT CHARACTERISTICS:

• Karnofsky performance status 80-100%

• Bilirubin = 2.0 mg/dL

• AST and ALT = 2 times upper limit of normal

• Creatinine = 2.0 mg/dL

• WBC = 3,000/mm^3

• Hemoglobin = 11.0 g/dL

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 125,000/mm^3

• No history of gastrointestinal malabsorption or other condition affecting drug absorption

• No history of food allergy to tomato-based products

• No history of any chronic medical condition that, in the judgment of the investigator, may pose threat or additional risk to the patient (including a current history of alcohol or drug abuse)

• No active history of cancer or other illnesses that, in the opinion of the investigator, could represent a threat to patient's life, including congestive heart failure or uncontrolled hypertension

PRIOR CONCURRENT THERAPY:

• No participation in any other experimental trial within the past 4 weeks

• No concurrent chronic use of nonsteroidal anti-inflammatory drugs

• No concurrent participation in another experimental trial

• No concurrent supplements (except multivitamins), including herbal and soy products

Study Design

Primary Purpose: Prevention

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Dietary Supplement:
• lycopene

Other:
• laboratory biomarker analysis

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Illinois at Chicago	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity as measured by NCI CTC v2.0			Yes
Primary	Feasibility of daily consumption of prescribed volumes of the formulation			No
Primary	Serum lycopene levels, including other carotenoids and lipid soluble vitamins, at 1 and 3 months			No
Primary	Pharmacokinetics at 1 and 3 months			No
Primary	Tissue distribution of lycopene (oral mucosa and prostate tissue)			No
Primary	Modulation of surrogate endpoint biomarkers which include oxidative stress in blood, oral mucosa, and prostate tissue			No
Primary	Modulation of serum prostate-specific antigen			No
Primary	Cellular proliferation as measured by proliferating cell nuclear antigen (PCNA)			No
Primary	Apoptosis as measured by Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling in prostate tissue			No
Primary	Serum levels of insulin-like growth factor (IGF-1) and the modulation of prostate histology (prostatic intraepithelial neoplasia [PIN], when and if present)			No